This article examines CCI's findings upon its market research on India's pharmaceutical industry.

Section 11(1)(d) tends to dilute the script of law by dissolving the thin line between permissible tax mitigation and tax avoidance.

The author explains the decision in Arcelor Mittal and thereafter examines the impact that it has on emergency awards in India.